What Limits Terminal Sterilization of PAM Methiodide in Multi-Dose Vials?

Aqueous compounding of a quaternary oxime salt intended for intravenous or intramuscular administration is constrained by two coupled variables: pH and dissolved oxygen. PAM methiodide contributes 48.06% w/w iodide, which means every 20 mg/mL solution carries approximately 9.61 mg/mL iodide. Free iodide is oxidized to iodine at sterilization temperatures when residual oxygen remains in bulk solution or headspace. Bulk mixing is therefore blanketed with nitrogen, and vial filling uses a nitrogen overlay on the holding tank. The pH is adjusted with hydrochloric acid or sodium hydroxide to 3.0–4.5; above 5.0, oxime degradation accelerates under thermal load. If terminal steam sterilization is used, the cycle is mapped with a minimum cold-spot F0 of 8 minutes at 121 °C chamber set point. Published thermal-degradation data specific to PAM methiodide are limited, and time-dependent color development is monitored at 420 nm during cycle development. A 20 mg/mL solution contributes approximately 151 mOsmol/L from the fully dissociated salt; tonicity is adjusted with sodium chloride to 280–300 mOsmol/kg. Filtration through 0.22 µm PVDF or PES membrane is performed before filling into Type I borosilicate vials. Container closure integrity is verified by USP <1207> dye-ingress method. Sterility is tested by membrane filtration per Ph. Eur. 2.6.1 with 14 days incubation. Bacterial endotoxin limits are calculated from the maximum bolus dose using the USP <85> K/M formula; for a 20 mg/kg dose and K = 5 EU/kg, the resulting limit is 0.25 EU/mg API. Sub-visible particulates are controlled by USP <788> Method 1 light obscuration, with acceptance criteria of not more than 6000 particles ≥ 10 µm and not more than 600 particles ≥ 25 µm per container for small-volume parenterals. The finished product is a clear, pale-yellow to yellow solution in 10 mL or 50 mL multi-dose vials, intended for slow intravenous injection in organophosphate toxicosis cases where atropinization alone is insufficient.

Before dry processing is initiated, the API lot must be conditioned to 25 °C ± 2 °C and 40% RH ± 5% RH for 48 h; if the storage environment exceeds 60% RH, the methiodide salt picks up moisture and roller compaction yields hard, colored ribbons. Dry granulation is preferred over wet granulation because aqueous binder contact with the quaternary oxime can generate a tacky mass, while tray drying above 50 °C increases iodide oxidation. A starting tablet formulation consists of 20% w/w PAM methiodide, 68.5% w/w microcrystalline cellulose PH-102, 10% w/w crospovidone, and 1.5% w/w magnesium stearate. Roller compaction is performed on a side-seal roller compactor with roll pressure 4–6 MPa, gap 1.5–2.0 mm, and sieve sizing through 0.8 mm mesh. Granule specifications target bulk density 0.45–0.60 g/mL, tapped density 0.55–0.75 g/mL, and Carr index below 25. Compression is run on a 10-station rotary tablet press with 8 mm tooling and target hardness 70–100 N. Dissolution is monitored per USP <711> Apparatus 2 paddle at 50 rpm in 900 mL of pH 6.8 phosphate buffer; a Q value of 80% at 30 minutes is used as the development target. Content uniformity follows USP <905> with acceptance value ≤ 15. The finished tablets are 50 mg or 100 mg strength, film-coated with an HPMC-based coat, and packaged in PVC/PVDC/aluminium blisters. Because the quaternary ammonium structure limits passive intestinal permeability, oral tablets are regarded as an adjunct or post-acute dosing form rather than a first-line emergency route; published pharmacokinetic data for PAM methiodide tablet administration in target species remain limited.

Powder-Layer Homogeneity During Capsule Filling of a Hygroscopic Quaternary Oxime

Segregation of a methiodide salt across the powder bed is driven by differences in bulk density and particle-size distribution. Capsule filling on an intermittent dosing-disc machine with a 0.5–1.0 mm dosing chamber height requires the API to be pre-blended with a densifier to reduce electrostatic adhesion. A formulation of 25% w/w PAM methiodide, 40% w/w spray-dried lactose monohydrate, 30% w/w microcrystalline cellulose PH-101, 4% w/w croscarmellose sodium, and 1% w/w sodium stearyl fumarate is filled into size 3 hard gelatin capsules at machine speeds below 30,000 capsules/h. Powder blend uniformity is verified at 10 sampling points with acceptance of 90.0–110.0% label claim and RSD ≤ 5.0% per Ph. Eur. 2.9.40. Environmental control at 25 °C ± 2 °C and 35% RH ± 5% RH is maintained; excursions above 50% RH require the powder hopper to be blanketed with dry nitrogen. The filled shells are dedusted and weight-sorted with rejection limits of ± 3% around the mean fill weight. Disintegration is tested per USP <701> in 800 mL water at 37 °C ± 2 °C; the target time is ≤ 15 minutes. Dissolution is evaluated using USP <711> Apparatus 1 basket at 100 rpm in 0.1 N hydrochloric acid followed by pH 6.8 buffer. The finished product is a 100 mg or 250 mg hard capsule supplied in cold-form aluminium blisters with silica gel desiccant. This format is used when a solid oral dose must be administered to companion animals that reject tablets; the same oral absorption limitation applies, and the capsule content should not be sprinkled onto alkaline feed because oxime degradation is accelerated above 7.5 pH.

Is Drinking-Water Medication of PAM Methiodide Feasible Under Commercial Broiler House Conditions?

Rapid dispersion of a water-soluble methiodide salt in drinking-water lines introduces failure modes that differ from those of parenteral or solid oral forms. In pH 7.0–7.8 hard drinking water, PAM methiodide may undergo accelerated oxidative discoloration within 24 h; the reaction is faster in galvanized steel pipes. Solutions are therefore prepared in polypropylene or high-density polyethylene stock tanks at ambient temperature, not in steel header tanks. A soluble powder for drinking water is blended as 50% w/w PAM methiodide with 49% w/w anhydrous dextrose and 1% w/w colloidal silicon dioxide. Target drinking-water concentration for the final medicated solution is typically 0.5 mg/mL to 2.0 mg/mL active ingredient, depending on species body weight and water intake; actual veterinary prescription overrides this developmental range. Dissolution time in 20 °C water at 2.0 mg/mL should be ≤ 5 minutes with gentle stirring. The pH of the medicated water is measured before administration and adjusted if necessary to 5.5–6.5 using citric acid buffer, because alkaline pH accelerates oxime decomposition. A UV spectrophotometric method at 295 nm can be used for line monitoring after filtration through a 0.45 µm membrane; method linearity should be confirmed between 0.1 mg/mL and 2.0 mg/mL. For field use, the solution is prepared fresh daily and is not stored for more than 6 h in direct sunlight. The finished product is a water-soluble powder in 100 g or 1 kg PET/aluminum foil pouches. Published stability data for PAM methiodide in chlorinated drinking-water lines are limited, but residual free chlorine above 0.5 ppm should be treated as an incompatibility because hypochlorous acid oxidizes the oxime functional group; water should be dechlorinated by standing or by sodium thiosulfate at 1–2 ppm before product addition.

When PAM Methiodide Is Adsorbed onto Feed-Grade Silica for Swine Premix Carryover Control

Because feed-grade precipitated silica has a tapped density below 0.35 g/mL, its use as a carrier for a high-iodine methiodide salt changes the segregation profile of a swine premix. A 10% w/w PAM methiodide premix is prepared by first blending the API with colloidal silica at 0.5% w/w of the total batch in a ribbon mixer at 20–25 rpm for 10 minutes. The API-silica premix is then extended with ground corn cob or rice hulls to 10% active content while maintaining moisture below 12% by Karl Fischer titration USP <921>. A horizontal paddle mixer with a mixing time of 8–10 minutes at complete fill is used for the final medicated feed; the target active concentration in final feed is 100–500 ppm, depending on prescribed dose and expected feed intake. Grain dust and fines below 250 µm should be minimized because the methiodide salt preferentially binds to high-surface-area dust and can create dead spots in auger systems. Carryover is validated by a tracer study with riboflavin or colored iron particles; acceptance is ≤ 2% cross-contamination in the following batch. The compliance boundary is not a feed-additive authorization because PAM methiodide is not a zootechnical feed additive under Regulation (EC) No 1831/2003; its use in feed under a veterinary prescription is governed by national cascade rules for medicated feedingstuffs, and the premix must be labeled with the prescribing veterinarian and withdrawal period if applicable. The finished product is a free-flowing 10% w/w premix in 25 kg multi-wall paper sacks with inner polyethylene liner. Material susceptible to caking at relative humidity above 65% should be stored below 30 °C.

Oral liquid presentation of PAM methiodide in polyolefin bottles requires a preservative system that does not promote oxime degradation. A 20 mg/mL oral solution is compounded with 0.1% w/w sodium benzoate or 0.05% w/w methyl paraben; benzoic acid is preferred because paraben solubility drops in the low-pH environment required for oxime stability. The vehicle is purified water with sorbitol solution at 20% w/w for palatability masking and glycerin at 5% w/w to raise viscosity and slow settling. pH is adjusted to 4.0–4.5 with citric acid, and the batch is sparged with nitrogen to reduce dissolved oxygen below 1 mg/L. Filling into amber polypropylene bottles is conducted at 20–25 °C under Class D cleanroom conditions. A 10 µm polypropylene clarification filter is used to remove undissolved salt. Microbial quality is tested by Ph. Eur. 5.1.4 with total aerobic microbial count ≤ 10² CFU/g and total combined yeasts/moulds ≤ 10¹ CFU/g. The finished solution is a clear light-yellow liquid labeled for oral administration in dogs and cats; light protection is critical because iodide-containing solutions darken under UV exposure. The bottle should be used within 30 days after first opening, as validated by in-use stability bracketing between 25 °C/60% RH and 40 °C/75% RH.